As therapeutic modalities diversify (ADCs, cell and gene therapies, RNAi), biopharma teams face growing complexity in selecting and prioritizing the right target–modality–indication (TMI) combinations. Each modality carries different maturity levels, risks, and capital needs, yet evaluation remains slow and fragmented. Retrospective, siloed tools make it hard to align opportunities with strategy, capabilities, and risk appetite.

The result: delayed go/no-go calls, higher burn, missed opportunities, and misallocated capital. What’s needed is a data-driven framework that connects scientific evidence with commercial viability to drive faster, more disciplined portfolio decisions.

Such a framework enables earlier, evidence-based triage; optimizes R&D allocation by focusing resources on the most promising programs; and improves pipeline productivity while minimizing the drag of failed assets. Most importantly, it creates the ability to seize first-mover opportunities in new therapeutic spaces, where timing can define market leadership.

‍

In this white-paper:

• Learn how to rapidly score target–modality–indication (TMI) options so go/no-go calls happen sooner, sunk costs fall, and pipeline productivity improves.
• See how modality-centric products compare competitor approaches to the same target, anticipate safety risks from clinical-trial signals (incl. AEs), and sharpen differentiation.
• Use responder vs non-responder profiles, single-cell atlases, and preclinical models (PDX/cell lines) to identify biomarkers and validate mechanisms before committing capital.
• Layer inclusion/exclusion criteria and outcomes from ClinicalTrials.gov to refine trial design, anticipate safety issues, and streamline regulatory preparedness.
  
• Implement the three-tier data-product architecture (target/modality/indication), a knowledge-graph with custom scoring, and an operating model that includes modular connectors (Open Targets, ClinicalTrials.gov , ChEMBL), LLM-based dataset discovery, harmonization to standard ontologies, and multi-layer QA/QC and governance.

‍